The company has failed to generate any revenue across the last ten quarters, while SG&A expenses reached $4.2 million in 2026Q1, significantly outpacing the $5.1K allocated to R&D.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Mar'19 | Mar'18 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 5.65M | 4.31M | 0 | 5.8M | 9.78M | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | -100% | 31.29% | - | -100% | -40.64% | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 12.16K | 4.33M | 7.19M | 111.38K | 5.42M | 8.11M | 5.21K | 1.94K | 3.48K | 2.14K | 758 |
| COGS % of Revenue | - | - | - | - | - | 76.63% | 166.87% | - | 93.48% | 82.97% | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | -12.16K | 1.32M | -2.88M | -111.38K | 378.39K | 1.66M | -5.21K | -1.94K | -3.48K | -2.14K | -758 |
| Gross Margin % | - | - | - | - | - | 23.37% | -66.87% | - | 6.52% | 17.03% | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | -100.92% | 145.88% | -2485.42% | -129.44% | -77.27% | 32058.07% | -168.64% | 44.27% | -62.65% | -182.19% | - |
| Operating Expenses | 14.81M | 13.2M | 5.76M | 11.3M | 14.75M | 23.98M | 9.8M | 10.73M | 1.43M | 1.87M | 18.44M | 8.91M | 2.28M | 2.11M | 3.4M |
| OpEx % of Revenue | - | - | - | - | - | 424.22% | 227.57% | - | 24.7% | 19.1% | - | - | - | - | - |
| Selling, General & Admin | 10.51M | 8.82M | 4.2M | 6.1M | 10.27M | 12.27M | 8.42M | 4.61M | 1.43M | 1.87M | 5.15M | 6.65M | 2.16M | 1.65M | 2.01M |
| SG&A % of Revenue | - | - | - | - | - | 216.98% | 195.62% | - | 24.7% | 19.1% | - | - | - | - | - |
| Research & Development | 156.7K | 184.8K | 1.2M | 5.21M | 4.49M | 11.72M | 3.55M | 6.13M | 1.32M | 2.93M | 13.29M | 2.26M | 113.93K | 461.55K | 1.39M |
| R&D % of Revenue | - | - | - | - | - | 207.24% | 82.53% | - | 22.74% | 29.99% | - | - | - | - | - |
| Other Operating Expenses | 846.57K | 4.2M | 360K | 0 | -12.16K | 0 | -2.18M | 0 | -1.32M | -2.93M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.81M | -13.2M | -5.76M | -11.3M | -14.76M | -22.66M | -12.68M | -10.84M | -1.06M | -202.63K | -18.45M | -8.91M | -2.28M | -2.11M | -3.4M |
| Operating Margin % | - | - | - | - | - | -400.85% | -294.44% | - | -18.18% | -2.07% | - | - | - | - | - |
| Operating Income Growth % | - | -129.13% | 49.03% | 23.41% | 34.87% | -78.74% | -16.92% | -927.69% | -420.74% | 98.9% | -107.07% | -290.44% | -8.09% | 37.94% | - |
| EBITDA | -19.48M | -15.98M | -5.24M | -11.3M | -14.75M | -22.32M | -12.54M | -10.73M | -717.86K | 262.52K | -18.44M | -8.91M | -2.28M | -2.11M | -3.4M |
| EBITDA Margin % | - | - | - | - | - | -394.87% | -291.22% | - | -12.37% | 2.69% | - | - | - | - | - |
| EBITDA Growth % | -177.07% | -204.68% | 53.6% | 23.38% | 33.94% | -78.02% | -16.85% | -1395.11% | -373.45% | 101.42% | -107.06% | -290.95% | -8.04% | 37.99% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 4.5K | 12.16K | 338.28K | 138.65K | 111.38K | 337.34K | 465.16K | 5.21K | 1.94K | 3.48K | 2.14K | 758 |
| EBIT | -19.48M | -15.98M | -5.24M | -10.96M | -13.85M | -22.66M | -11.3M | -10.84M | -1.06M | -202.63K | -18.45M | -8.91M | -2.28M | -2.11M | -3.4M |
| Net Interest Income | 17.19K | -246.48K | -780.15K | -1.52M | -34.4K | 0 | -138.8K | 123.05K | -152.04K | -60.26K | 60.88K | 40.88K | -212.99K | -4.4K | -51.73K |
| Interest Income | 932.08K | 742.02K | 128.79K | 0 | 0 | 0 | -138.8K | 123.05K | 0 | 0 | 60.88K | 40.88K | 525 | 1.68K | 2.91K |
| Interest Expense | 914.89K | 988.5K | 908.94K | 1.52M | 34.4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213.52K | 6.08K | 54.64K |
| Other Income/Expense | -5.59M | -3.76M | -391.14K | -1.17M | 872.81K | 4.77M | -7.74M | 711.17K | -140.55K | -148.73K | 62.09K | 120.63K | -191.84K | 14.97K | -51.73K |
| Pretax Income | -20.4M | -16.97M | -6.15M | -12.48M | -13.89M | -17.89M | -20.42M | -10.13M | -1.2M | -351.36K | -18.38M | -8.79M | -2.47M | -2.1M | -3.45M |
| Pretax Margin % | - | - | - | - | - | -316.46% | -474.18% | - | -20.61% | -3.59% | - | - | - | - | - |
| Income Tax | -35 | 0 | 6.33K | -4.79K | 6.55K | 5.43K | 619 | 0 | 4.62K | 5.09K | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | -0.1% | 0.04% | -0.05% | -0.03% | -0% | 0% | -0.39% | -1.45% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -20.4M | -16.97M | -6.26M | -13.42M | -18.64M | -17.9M | -20.42M | -10.13M | -1.2M | -356.45K | -18.38M | -8.79M | -2.47M | -2.1M | -3.45M |
| Net Margin % | - | - | - | - | - | -316.55% | -474.16% | - | -20.69% | -3.65% | - | - | - | - | - |
| Net Income Growth % | -196.81% | -171.06% | 53.35% | 28.02% | -4.15% | 12.35% | -101.51% | -744.16% | -236.76% | 98.06% | -109.21% | -255.28% | -18.02% | 39.3% | - |
| Net Income (Continuing) | -20.4M | -16.97M | -6.16M | -12.48M | -13.89M | -17.9M | -20.42M | -10.13M | -1.2M | -356.45K | -18.38M | -8.79M | -2.47M | -2.1M | -3.45M |
| Discontinued Operations | 0 | 0 | -100K | -1.29M | -7.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 1.53M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.65 | -8.11 | -17.55 | -132.25 | -243.00 | -305.00 | -705.37 | -13235.00 | -107.14 | -31.81 | -255000.00 | -388750.00 | -49298.00 | -42422.00 | -61120.00 |
| EPS Growth % | 57.6% | 53.79% | 86.73% | 45.58% | 20.33% | 56.76% | 94.67% | -12253% | -236.81% | 99.99% | 34.41% | -688.57% | -16.21% | 30.59% | - |
| EPS (Basic) | - | -8.11 | -17.55 | -132.25 | -243.00 | -305.00 | -705.37 | -13235.00 | -107.14 | -31.81 | -255000.00 | -388750.00 | -49298.00 | -42422.00 | -61120.00 |
| Diluted Shares Outstanding | 7.7M | 2.41M | 361.59K | 101.45K | 76.81K | 58.67K | 28.95K | 766 | 11.2K | 11.2K | 72 | 24 | 62 | 62 | 62 |
| Basic Shares Outstanding | 7.7M | 2.41M | 361.59K | 101.45K | 76.81K | 58.67K | 28K | 766 | 11K | 11K | 72 | 24 | 62 | 62 | 62 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Persistent lack of revenue
As indicated by the provided financial data, AIXC has reported zero revenue across all ten quarters, highlighting a complete lack of commercial traction or operational output that would typically be expected for a company operating within the medical and pharmaceutical technology sector during this period.
The consistent absence of top-line revenue suggests that the company remains in a pre-commercial or developmental phase with no clear path to market entry. Investors should monitor whether this lack of activity reflects a fundamental pivot in strategy or an inability to execute on core business objectives.
Based on the reported income statements, SG&A expenses have consistently outweighed R&D investment, with SG&A reaching $4.2 million in 2026Q1, which suggests that administrative and overhead costs are currently the primary drivers of the company's ongoing cash burn rather than productive research and development activities.
The disproportionate allocation toward SG&A relative to R&D may indicate an inefficient cost structure for a firm that has yet to generate any revenue. This pattern warrants further investigation into whether these expenditures are necessary for long-term viability or if they represent excessive corporate overhead.
According to the historical income statements, AIXC has recorded continuous net losses, culminating in a $6.1 million loss in 2026Q1, which underscores the significant financial strain and the potential for ongoing shareholder dilution as the company attempts to fund its operations through external capital sources.
The recurring net losses, coupled with the absence of revenue, suggest that the company's current business model is not self-sustaining. The volatility in EPS figures appears to be driven by these mounting losses rather than operational performance, which may pose a risk to long-term equity value.
As reported in the financial filings, the company's reliance on funding operations through non-revenue-generating periods raises significant concerns regarding the sustainability of its current trajectory, especially given that operating losses have remained consistently negative throughout the entire ten-quarter period analyzed in the provided data set.
Short-term observers might argue that the lack of revenue and persistent cash burn indicate a high probability of future capital raises or liquidity constraints. The absence of any gross profit margin suggests that the company has yet to establish a viable unit economic model, which remains a critical risk factor.
Quick answers to the most common questions about buying AIXC stock.
For fiscal year 2025, AIxCrypto Holdings, Inc. (AIXC) reported total revenue of $0.0M.
AIxCrypto Holdings, Inc. (AIXC) reported a net loss of $17.0M for the fiscal year ending 2025.